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Abstract
We show that cell surface glycans, sialic acid and mannose-containing species, are involved beside glycosaminoglycans
(GAGs), heparan sulfate and chondroitin sulfate in the binding of full length (1^68) RANTES not only to CCR5 positive
human primary lymphocytes or macrophages but also to CCR5 negative monocytic U937 cells. Pretreating the cells with
neuraminidase, heparitinase, chondroitinase or adding soluble glycans such as mannan or GAGs (heparin or chondroitin
sulfate), significantly inhibited RANTES binding. Such effects were not observed with truncated (10^68) RANTES. Heat-
denaturation of (1^68) RANTES strongly decreased its binding to the cells, demonstrating involvement of the three-
dimensional structure. Accordingly, full length, but not truncated (10^68) RANTES, specifically bound to soluble mannan as
well as to mannose-divinylsulfone-agarose affinity matrix and to soluble heparin or chondroitin sulfate as well as to heparin-
agarose. Soluble heparin exerts, depending on its concentration, inhibitory or enhancing effects on RANTES binding to
mannose-divinylsulfone-agarose, which indicates that RANTES interaction with glycans is modulated by GAGs. These data
demonstrate that full length RANTES, but not its (10^68) truncated counterpart, interacts with glycans and GAGs, in
soluble forms or presented either by affinity matrices or CCR5 positive as well as CCR5 negative cells. ß 2001 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Infection of target cells by human immunode¢-
ciency virus type 1 (HIV-1) is mediated by interac-
tions of the HIV envelope glycoproteins with CD4
and a coreceptor [1^3]. The preferential tropism of
di¡erent HIV strains for either macrophages or
transformed CD4 cell lines is related to their use
of di¡erent coreceptors [1^3]. The major coreceptor
of X4 HIV strains is CXCR4 [1,4^6], the physiolog-
ical ligand of which is K chemokine stromal-cell-de-
rived factor (SDF)-1K [4,5]. CXCR4, also present on
macrophages [7], is not used for entry by R5 strains
that use CCR5, the receptor of L chemokines
RANTES (regulated on activation normal T cell ex-
pressed and secreted), macrophage in£ammatory
protein (MIP)-1K and MIP-1L [8,9]. The ligands of
0005-2736 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 0 0 5 - 2 7 3 6 ( 0 0 ) 0 0 3 6 8 - 0
Abbreviations: RANTES, regulated on activation normal T
cell expressed and secreted; GAG, glycosaminoglycan; PL, pe-
ripheral lymphocytes; MDM, monocyte-derived macrophages;
SDF, stromal-cell-derived factor; HIV, human immunode¢ciency
virus; MIP, macrophage in£ammatory protein; C50, 50% inhibit-
ing concentration
* Corresponding author. Fax: +33-1-48026503;
E-mail : liliane.gattegno@jvr.ap-hop-paris.fr
BBAMEM 78027 30-1-01
Biochimica et Biophysica Acta 1510 (2001) 354^366
www.elsevier.com/locate/bba
these receptors can modify, in vitro, HIV-1 infection
in several ways, the most commonly observed being
inhibition of virus entry because of competition be-
tween the virus and the chemokine for binding sites
on the same receptor [9^11]. While some chemokines
have been shown to bind to glycosaminoglycans
(GAGs) [12], the role of GAGs binding properties
on receptor binding or signaling has not been clearly
established [12^14]. However, after enzyme digestion
of their membrane GAGs, some cell lines or human
primary macrophages are resistant to the antiviral
e¡ects of RANTES and MIP-1L for R5 HIV strains
[10,15]. There is some controversy concerning the
quaternary structure of biologically active chemo-
kines when they bind to receptors, with evidence to
suggest either monomers, dimers or higher molecular
weight associations [16,17]. Not all chemokines self-
associate, leading to the question of the biological
signi¢cance of such an association. RANTES has
been shown to self-associate [16,17] and to inhibit
[15,18] or increase [19] in vitro HIV infection. It
has been reported that one mechanism of infectivity
enhancement may be caused by cross-linking of HIV
virions to cell surfaces by oligomers of the RANTES
form after binding to GAGs [19] and that a second
mechanism of viral infectivity enhancement arises
from the prolonged interaction of RANTES oligo-
mers with cell surface GAGs, which activates a
herbimycin A-sensitive, tyrosine-kinase-dependent
signal transduction [19]. In addition, it has been
demonstrated that aggregation of WM concentra-
tions of RANTES is responsible for its in£amma-
tory properties [16]. However, RANTES serum
levels are respectively 2.2 nM in healthy HIV sero-
negative patients and 3.5 nM in HIV-infected pa-
tients [20].
The aim of this study was to test whether
RANTES, at nM concentrations, close to those ob-
served in human sera, interacts, like SDF-1 [21] and
gp120 of X4 strain HIV-1lai [22^26], not only with
soluble or cellular GAGs, as previously described
[10,14,15], but also with soluble or cellular glycans
presented by CCR5 negative (CCR53) or CCR5
positive (CCR5+) cells. The behavior of synthetic
full length (1^68) RANTES was compared with
that of truncated (10^68) RANTES in order to de-
termine the role of the chemokine N-terminus do-
main on its carbohydrate-binding properties.
2. Materials and methods
2.1. (1^68) and (10^68) RANTES radiolabeling
Synthetic (1^68) and (10^68) RANTES (gifts from
C. Vita, CEA, Saclay, France) were synthesized on a
fully automatic peptide synthesizer (Applied Biosys-
tems Model 433, Foster City, CA, USA) on a mmol
scale according to the FastMoc protocol [27]. Purity
was tested by analytical HPLC and capillary electro-
phoresis. Identity of the puri¢ed products was veri-
¢ed by amino acid analysis and mass spectrometry.
It was previously reported that the binding a⁄nities
of synthetic RANTES for CD4+ CCR5+ cells were
similar to those observed for recombinant RANTES
[28]. In the present study, synthetic (1^68) and (10^
68) RANTES were radiolabeled with iodobeads
(Pierce Europe, BA, Oud-Beijerland, The Nether-
lands) according to the manufacturer’s instructions.
Speci¢c activities were about 0.2^0.7 MBq/Wg. Io-
dide-labeled (1^68) RANTES was analyzed by elec-
trophoresis on polyacrylamide gels (16%), in native
(PAGE) and in denaturing and reducing conditions
(SDS-PAGE).
2.2. Cells
CCR53 CD4+ CXCR4+ cells of the monocytic
U937 line were cultured at 37‡C in RPMI 1640,
10% heat-inactivated fetal calf serum (FCS, Bio-
Whittaker, Emarainville, France), 1% penicillin/
streptomycin, 1% L-glutamine (Gibco BRL, Paisley,
UK).
To prepare peripheral lymphocytes (PL) and
MDM, Ficoll^Hypaque-separated blood mononu-
clear cells (PBMC) of healthy volunteers (Seine-
Saint-Denis or Pitie¤-Salpe“trie're Blood Banks) were
cultured at 2^5U106 cells/ml for 5 days, in RPMI
1640, 1% penicillin/streptomycin, 1% L-glutamine
(Gibco BRL), 20% FCS (Boehringer Mannheim,
Germany), 10% heat-inactivated normal human
pooled AB serum (Seine Saint-Denis blood bank)
[15,18,29]. Nonadherent cells which represent more
than 90% T or B CD3+ or CD19+ lymphocytes, as
assessed by immuno£uorescent labeling with FITC-
conjugated mAb anti-CD3 and anti-CD19 mAb
(Becton Dickinson Immunocytometry, Mountain
View, CA, USA), followed by £ow cytometry analy-
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sis with a FACScan (Becton Dickinson Immunocy-
tometry), were then removed by several washes in
Ca2- and Mg2-free phosphate-bu¡ered saline
(PBS).
Adherent cells were cultured in the same medium
without AB serum, but with 20% FCS for another
24^48 h, before they were subjected to binding ex-
periments as adherent cells or scraped o¡ with a
rubber policeman. This procedure yielded s 90%
CD14+ viable MDM that expressed CCR5 and low
membrane CD4 as reported [15,18,29]. No contami-
nating T cells were noted under these conditions
(data not shown).
The cells (5U105 in 100 Wl PBS, 0.05% BSA,
0.05% sodium azide) (PBS-BSA-A) were incubated
for 30 min at 4‡C with 2.5 Wg mAb anti-CCR5, spe-
ci¢c for the second extracellular loop (2D7) or with
2.5 Wg anti-CXCR4 mAb12G5 (both from Pharmin-
gen, San Diego, CA, USA) or with 2.5 Wg of the
isotype control (IgG2a; Sigma). Cells were then
washed and incubated for 30 min at 4‡C in 100 Wl
of FITC-labeled anti-mouse immunoglobulin goat
antibodies (Coulter Coultronics, France) diluted
1/20 in bu¡er. In parallel, cells were incubated for
30 min at 4‡C in PBS-BSA-A with 1 Wg FITC-CD4
(clone 13B.8.2) or its isotype control (1 Wg; IgG1-
FITC) both from Immunotech, Marseille, France
or with FITC-labeled speci¢c lectins (0.75^1 Wg/ml;
RCA120 speci¢c for L-galactosyl, erythrina cristagal-
li speci¢c for GalL1^4GlcNAc, lathyrus odoratus
speci¢c for K-mannose and GlcNAc and concanava-
lin A speci¢c for K-mannose and K-glucose (all from
Sigma or Boehringer, Mannheim, Germany). After
three washes at 4‡C, cells were ¢xed in 1% paraform-
aldehyde (Sigma) in PBS (500 Wl) and analyzed by
£ow cytometry. Data were analyzed using CELL Ly-
sis (Becton Dickinson Immunocytometry).
2.3. Enzyme treatment
An amount of 5U105 cells was incubated for 1 h
at 37‡C in 50 Wl PBS, 0.05% BSA, and 1 mU hepar-
itinase (heparitin sulfate eliminase, EC 4.2.2.8) or
chondroitinase (chondroitinase ABC eliminase, EC
4.2.2.4), both from Sigma (St Louis, MO, USA) or
2 mU neuraminidase (Boehringer, Mannheim, Ger-
many) supplemented or not with protease inhibitors
(10 mM PMSF, 25 mM phenanthroline, 5 mM iodo-
acetamide, 100 Wg/ml aprotinin, all from Sigma). The
enzymes were not toxic for the cells, as assessed by
trypan blue exclusion.
2.4. (1^68) and (10^68) RANTES binding to the
cells
Cells (5U105) in 100 Wl RPMI 1640, 0.05% BSA
(RPMI-BSA) were incubated for 2 h at 4‡C with 50
Wl of native or heat-treated (10 min at 100‡C, in the
presence of 0.3% L-mercaptoethanol) [125I](1^68) or
[125I] (10^68) RANTES (0.5U105 cpm; 3U1039 M).
After two washes (700Ug, 10 min, 4‡C), cell-bound
radioactivity was measured with a Q counter (LKB,
Paris, France). The e¡ect of heparitinase, chondroi-
tinase or neuraminidase on native [125I](1^68)
RANTES binding to the cells was determined. In
parallel, the e¡ect of heparin (sodium salt, from por-
cine intestinal mucosa), mannan (from Saccharomy-
ces cerevisiae), chondroitin sulfate (70% chondroitin
sulfate A; sodium salt from bovine trachea) or dex-
tran (up to 330 Wg/ml; all from Sigma), or a mix of
these compounds, on native [125I](1^68) or [125I] (10^
68) RANTES binding to the cells was examined, at
di¡erent concentrations that did not alter cell viabil-
ity, as follows: [125I] RANTES in RPMI-BSA was
incubated for 60 min at 37‡C with di¡erent concen-
trations of heparin, chondroitin sulfate, mannan or
dextran, and the mixture was then added to the cells
and incubated as described above. In some experi-
ments, mixes of these compounds, were incubated
with native [125I](1^68) RANTES. In some experi-
ments, cells were preincubated for 45 min at 4‡C
with anti-CCR5 mAb 2D7 or its isotype control
(IgG2a) (both at 25 Wg/ml), and the mixture was
incubated with native [125I](1^68) RANTES as de-
scribed above.
2.5. (1^68) or (10^68) RANTES binding to heparin
or mannose either in solution or presented by
heparin-agarose or mannose-divinylsulfone-
agarose
Binding of native or heat-treated (10 min at 100‡C,
in the presence of 1% SDS, 5% L-mercaptoethanol)
[125I](1^68) or [125I] (10^68) RANTES (0^12 nM) to
heparin-agarose (Sigma) or to mannose-divinylsul-
fone-agarose (E.Y Laboratories, San Mateo, CA,
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USA) was investigated as follows: 20 Wl of a⁄nity
matrix were suspended in an equal volume of bu¡er
0.02 M Tris, 0.15 M NaCl, 0.01 M CaCl2, 0.05%
BSA, pH 7.4 (Tris^Ca^BSA). After incubation for
1 h at 37‡C, unbound RANTES was washed out
twice in 500 Wl of bu¡er. Solid phase-bound radio-
activity was counted, and the results were expressed
as means of duplicates of at least three independent
experiments. The physicochemical characteristics of
the interaction were analyzed by performing the as-
says under di¡erent conditions: [125I] RANTES di-
luted in 50 Wl of bu¡er was incubated with 20 Wl
a⁄nity matrix in 0.02 M Tris, 0.15 M NaCl, 0.05%
BSA bu¡er (Tris^BSA), pH 7.4, supplemented by
0^0.01 M CaCl2 or by 0.01 M disodium salt
EDTA (Sigma); or the experiments were conducted
in Tris^Ca^BSA at 4, 20 or 37‡C, or at di¡erent pH
ranging from 4 to 8.2. In parallel, native [125I](1^68)
or [125I] (10^68) RANTES was preincubated for
45 min at 37‡C with 0^330 Wg/ml heparin, chondroi-
tin sulfate, mannan or dextran (all from Sigma), be-
fore adding the a⁄nity matrix (20 Wl). Coincubation
was then performed as above. Unbound [125I]
RANTES was washed out and bound radioactivity
was counted.
Reversal of RANTES binding to heparin-agarose
or mannose-divinylsulfone-agarose was investigated
as follows: 250 Wl of [125I](1^68) RANTES (3^9
nM) were incubated for 1 h at 37‡C with 250 Wl of
a⁄nity matrices in Tris^Ca^BSA. Unbound [125I]-
(1^68) RANTES was washed out thrice in 1 ml of
bu¡er, and the matrix was incubated at 20‡C for 5 h
with gentle shaking in 250 Wl bu¡er supplemented or
not with heparin, mannan dextran or methyl-K-man-
nose (5 mg/ml). Unbound and speci¢cally reversed
molecules were then analyzed by SDS-PAGE (16%)
in native or denaturing conditions. In some experi-
ments, native [125I](1^68) RANTES (3^9 nM) was
preincubated for 1 h at 37‡C in Tris^BSA, Tris^
EDTA, Tris^BSA supplemented with 2.5 or 10 mM
CaCl2, in PBS, or in Tris^Ca^BSA supplemented
with mannan, heparin or dextran (all at 330 Wg/ml)
and analyzed by PAGE (16%) in native conditions.
2.6. (1^68) RANTES binding to dotted mannan
Mannan or dextran (5 Wg) were dotted onto nitro-
cellulose strips; strips were then incubated with 106
cpm of [125I](1^68) RANTES for 2 h at 37‡C. After
six washes, strips were exposed at 320‡C for 48 h.
Alternatively, [125I](1^68) RANTES was preincu-
bated for 45 min at 37‡C with 5 mg/ml of mannan,
heparin, or dextran before incubation with the strips,
during which the compounds were maintained at the
initial concentration.
3. Results
3.1. Cell surface glycans and GAGs mediate (1^68)
RANTES binding to CCR5+ primary
lymphocytes, macrophages and
CCR53 monocytic U937 cells
In the present study, no exogenous cytokine was
added, but the monocyte-derived macrophages
(MDM), were ¢rst cultured in the presence of autol-
ogous lymphocytes, which may release endogenous
cytokines, before lymphocytes were carefully washed
away. During cell coculture, the MDM may also
release endogenous cytokines. In these conditions,
45^60% of the primary lymphocytes (PL) clearly ex-
pressed CD4, while a low amount of CD4 was de-
tected on all the MDM (Fig. 1); all the PL and
MDM expressed CCR5 and CXCR4, while the
U937 cells expressed CD4 and CXCR4, but not
CCR5 (Fig. 1).
We next examined whether full length [125I](1^68)
RANTES bound to CCR53 U937 cells as well as to
CCR5+ PL and MDM.
[125I](1^68) RANTES bound in a dose-dependent
manner to each cell type; the binding was signi¢-
cantly inhibited by heat-treatment of the chemokine,
demonstrating the involvement of RANTES three-
dimensional structure (Table 1 and data not shown).
We have already reported [18] that in agreement with
Ben Baruch et al., [30], a 10-fold molar excess of cold
(1^68) RANTES only partially competed with the
binding of [125I](1^68) RANTES to MDM and that
a 100^250-fold excess of cold (1^68) RANTES led to
increased binding of [125I](1^68) RANTES, which
was related to aggregates of cold and [125I](1^68)
RANTES. Therefore, in the present study we consid-
ered that non-speci¢c [125I](1^68) RANTES binding
to the cells was that of the heat-denatured [125I]-
(1^68) chemokine, which was a mean of 21, 47 and
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5% of the total bound radioactivity by respectively
PL, MDM and U937 cells (Table 1).
[125I](1^68) RANTES binding to primary CCR5+
PL and CCR5+ MDM, but not as expected to
CCR53 U937 cells, was signi¢cantly, inhibited by
anti-CCR5 mAb, 2D7, speci¢c for the second extra-
cellular loop (ECL2) (Table 1); this indicates, as ex-
pected, CCR5 involvement in RANTES attachment
to the CCR5+ cells.
We next analyzed the role of cellular glycans and
GAGs in (1^68) RANTES binding to the cells. For
this purpose, the cells were pretreated by neuramin-
idase, heparitinase or chondroitinase. Neuraminidase
treatment increased their binding to FITC-labeled
RCA and erythrina cristagalli, speci¢c for L-galac-
tose residues, demonstrating e⁄ciency of this enzyme
treatment (data not shown). The e⁄ciency of hepar-
itinase or chondroitinase treatment was previously
tested by a metabolic labeling during a 20 h culture
in a medium supplemented with [35S]04 [21].
In the present study, we observed that not only
heparitinase but also chondroitinase or neuramini-
dase pretreatment of the cells, partially, but signi¢-
cantly inhibited [125I](1^68) RANTES binding (Table
1). These data indicate that (1^68) RANTES attach-
ment to CCR5+ PL, CCR5+ MDM and also to
CCR53 U937 cells occurs not only through heparan
sulfate but also through chondroitin sulfate and
sialic acid-containing glycans.
Alternatively, we examined whether soluble gly-
cans as well as soluble GAGs (heparin or chondroi-
tin sulfate) competed with (1^68) RANTES binding
not only to CCR5+ cells but also to CCR53 cells.
We ¢rst observed that [125I](1^68) RANTES binding
to the cells was partially but signi¢cantly inhibited
not only by heparin but also by chondroitin sulfate;
in addition, soluble mannan had also a signi¢cant
inhibitory e¡ect, with indicates that mannose-con-
taining species were also involved in this interaction
(Tables 2 and 3). These inhibitions were dose-depen-
Fig. 1. MDM, U937 cells and PL and membrane expression of CD4 and chemokine receptors. MDM, PL and U937 cells were labeled
with CD4 (by direct immuno£uorescence assay), CCR5, and CXCR4 mAb (by indirect immuno£uorescence assay) (black peaks) or
with isotype control antibodies (white peaks). Data are representative of two to four di¡erent experiments.
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dent (data not shown). Concentrations for maximum
inhibitions were respectively 0.3^3 Wg/ml for the
CCR5+ PL, 33 Wg/ml for the CCR5+ MDM and
330 Wg/ml for the CCR53 U937 cells, which demon-
strates that higher concentrations of soluble GAGs
or glycans are required to inhibit RANTES binding
to the CCR53 U937 cells as compared to the
CCR5+ MDM or the CCR5+ PL. Dextran had no
signi¢cant e¡ect, except for binding to PL (Tables 3
and 4). Most of these e¡ects were additive (Tables 2
and 3).
These data strongly indicate that beside heparin,
another GAG-chondroitin sulfate as well as glycans,
have a role in (1^68) RANTES attachment not only
to CCR5+ cells but also to CCR53 cells.
However, the fact that soluble heparin, chondroi-
Table 2
E¡ect of soluble mannan, heparin, chondroitin sulfate or mixes of these compounds on [125I](1^68) RANTES binding to primary lym-










Control 7500 þ 1600 5810 þ 1550
Heparin 4100 þ 940*** 45 þ 5 3230 þ 740** 42 þ 13
Dextran 5100 þ 1380* 32 þ 7 7340 þ 3000 8 þ 8
Mannan 4800 þ 1100*** 35 þ 11 4240 þ 1800* 32 þ 20
Chondroitin sulfate 5780 þ 1010** 27 þ 13 4096 þ 1088*** 30 þ 3
Heparin+chondroitin sulfate 3000 þ 900* 60 þ 7 1900 þ 900* 67 þ 16
Heparin+mannan 2400 þ 800* 68 þ 14 1700 þ 400* 71 þ 4
Mannan+chondroitin sulfate 3500 þ 200* 54 þ 3 2320 þ 50** 60 þ 1
Heparin+chondroitin sulfate+mannan 2200 þ 200* 71 þ 4 1370 þ 400* 77 þ 12
Native [125I](1^68) RANTES (3 nM; 50 000 cpm) (control) was incubated for 1 h at 37‡C with 0^330 Wg/ml of heparin, dextran, man-
nan or chondroitin sulfate or mixtures of these compounds. The mixture was added to the cells, and incubated for 2 h at 4‡C. Con-
centrations for maximum inhibitions were 0.3^3 Wg/ml for lymphocytes and 33 Wg/ml for macrophages. Results are presented as
means þ S.D. of the maximum inhibition observed in four to nine independent experiments performed in duplicate. The statistical sig-
ni¢cance of di¡erences relative to controls was determined by the paired Student’s t-test : *P6 0.02; **P6 0.01; ***P6 0.001.
Table 1
E¡ect of anti-CCR5 2D7 mAb, heparitinase, chondroitinase and neuraminidase treatment on [125I](1^68)RANTES binding to primary
lymphocytes, monocyte-derived macrophages and U937 cells













Native [125I]RANTES 9620 þ 1320 7570 þ 2600 11500 þ 3000
Anti-CCR5 2D7 mAb 4320 þ 1000* 55 þ 10 4010 þ 1000* 47 þ 12 11500 þ 2000 0
IgG2a 9600 þ 1200 0 7500 þ 1500 0 11500 þ 2000 0
Heparitinase 5715 þ 1320*** 41 þ 8 5730 þ 1350* 22 þ 6 6740 þ 3000*** 45 þ 17
Chondroitinase 6470 þ 880** 31 þ 15 5600 þ 1600**** 25 þ 5 7200 þ 2700** 35 þ 5
Neuraminidase 6010 þ 1000* 43 þ 6 4580 þ 2500*** 48 þ 17 6020 þ 2000* 42 þ 25
Heat-treated
[125I]RANTES
2020 þ 800* 79 þ 8 3558 þ 1000* 53 þ 10 600 þ 150*** 95 þ 2
Native or heat-treated (10 min at 100‡C) [125I](1^68) RANTES (3 nM; 50000 cpm), was incubated for 2 h at 4‡C with the cells. In
parallel, the cells were preincubated for 1 h at 4‡C in the presence or the absence of anti-CCR5 2D7 mAb or the isotype control,
IgG2a (2.5 Wg, each), mixes were then incubated, as described above, with native [125I](1^68) RANTES. Enzyme-treated or untreated
cells were incubated with native [125](1^68) RANTES for 2 h at 4‡C. Results are means þ S.D. of three to eight independent experi-
ments performed in duplicate. The statistical signi¢cance of di¡erences relative to controls was determined by the paired Student’s
t-test *P6 0.05; **P6 0.01; ***P6 0.001; ****P6 0.02.
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tin sulfate or mannan did not signi¢cantly compete
with the binding of radiolabeled truncated (10^68)
RANTES to the CCR53 U937 cells or the CCR5+
PL strongly indicates the involvement of the N-ter-
minus domain of RANTES in its interactions with
soluble or cellular GAGs and glycans (Table 3 and
data not shown).
Table 4
[125I](1^68) RANTES or [125I](10^68) RANTES binding to heparin-agarose or mannose-divinylsulfone-agarose










Control 8130 þ 3500 8010 þ 1945
Heparin 4075 þ 2700** 53 þ 16 6225 þ 1210** 21 þ 8
Chondroitin sulfate 10325 þ 4500 0
Dextran 8560 þ 4000 0 7600 þ 1940 2 þ 2
Mannose-divinylsulfone-agarose
Control 27750 þ 5675 7810 þ 1905
Mannan 7415 þ 1450**** 73 þ 3a 6100 þ 1280* 21 þ 5
Heparin 8750 þ 730*** 70 þ 4b 5140 þ 1280* 29 þ 8
Chondroitin sulfate 9160 þ 1640*** 68 þ 11 8930 þ 3855 0
Dextran 25935 þ 4050 0 7280 þ 2270 3 þ 3
[125I](1^68) RANTES or [125I](10^68) RANTES (3^6 nM; 50 000^100 000 cpm) was incubated for 1 h at 37‡C with heparin, mannan,
chondroitin sulfate or dextran, and the mixture was then added to the matrix. Results are presented as means þ S.D. of three to nine
experiments performed in duplicate. Concentrations for maximum inhibition are 330 Wg/ml. The statistical signi¢cance of di¡erences
relative to controls was determined by the paired Student’s t-test: *P6 0.05; **P6 0,02; ***P6 0.01; ****P6 0.001.
aC50 = 18 Wg/ml.
bC50 = 160 Wg/ml.
Table 3
E¡ect of mannan, heparin, chondroitin sulfate or mixtures of these compounds on [125I](1^68) and (10^68) RANTES binding to U937
cells









Control 5230 þ 1500 2190 þ 440
Heparin 2290 þ 780** 56 þ 12 1825 þ 410 17 þ 10
Dextran 4960 þ 2350 11 þ 4 2250 þ 605 0
Mannan 3460 þ 350* 24 þ 9 3110 þ 1290 0
Chondroitin sulfate 3880 þ 2150* 28 þ 20 3480 þ 605 0
Heparin+mannan 1950 þ 600** 63 þ 14
Chondroitin sulfate+mannan 2300 þ 700** 57 þ 14
Heparin+chondroitin sulfate 2300 þ 650** 55 þ 14
Heparin+chondroitin sulfate+mannan 1800 þ 600** 67 þ 15
[125I](1^68) or (10^68) RANTES (3 nM; 30 000^50 000 cpm) was incubated for 1 h at 37‡C with 0^330 Wg/ml of heparin, dextran,
mannan or chondroitin sulfate or mixtures of these compounds. The mixture was added to the cells, and incubated for 2 h at 4‡C.
Results are presented as means þ S.D. of the maximum inhibition observed in three to ¢ve independent experiments performed in du-
plicate. The C50 of heparin was 160 Wg/ml. The statistical signi¢cance of di¡erences relative to controls was determined by the paired
Student’s t-test: *P6 0.05; **P6 0.01.
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3.2. Binding of (1^68) RANTES to heparin-agarose
or mannose-divinylsulfone agarose
According to these ¢ndings, we next examined
whether full length (1^68) RANTES interacts with
heparin or mannose either in solution or presented
by a⁄nity matrices, heparin-agarose or mannose-di-
vinylsulfone-agarose. [125I](1^68) RANTES bound in
a dose-dependent manner not only to heparin-aga-
rose, as expected, but also to mannose-divinylsul-
fone-agarose (Figs. 2a and 3a). The chemokine
heat-denaturation strongly and signi¢cantly de-
creased these bindings, which indicates involvement
of its three-dimensional structure (Figs. 2e and 3e).
The percent of inhibition induced by the chemokine
heat-treatment in the presence of SDS and L-mercap-
toethanol were respectively 90 þ 2 and 87 þ 3 for hep-
arin-agarose and mannose-divinylsulfone-agarose
(P6 0.001 and 6 0.01; n = 4). As aggregation of
RANTES has been reported [30], non-speci¢c
[125I](1^68) RANTES binding to the matrices was
therefore considered here as the binding of heat-
treated [125I](1^68) RANTES in the presence of
SDS and L-mercaptoethanol which was respectively
6^12% for heparin-agarose and 6^16% for mannose-
divinylsulfone-agarose of the total bound radioactiv-
ity (Figs. 2e and 3e). Binding to mannose-divinylsul-
fone-agarose was strongly dependent on tempera-
ture, while binding to heparin-agarose was only
slightly increased at 37‡C as compared to 4 and
20‡C (Figs. 2b and 3b). Both bindings were strongly
pH-dependent, increasing from pH 7 up to 7.8, with
a maximum at pH 7.8, for mannose-divinylsulfone-
agarose and from pH 5 to 8.2 for heparin-agarose
(Figs. 2c and 3c). Binding to heparin-agarose was
Ca2-independent (Fig. 2d) and was not prevented
when EDTA was added before initiation of the re-
action (data not shown); on the contrary, binding to
mannose-divinylsulfone-agarose was strongly Ca2-
dependent, prevented by EDTA added before initia-
tion of the reaction (Fig. 3d). This calcium depen-
C
Fig. 2. In£uence of physicochemical conditions on the binding
of full length (1^68) RANTES to heparin-agarose. (a) RANTES
concentration: [125I](1^68) RANTES was incubated for 1 h at
37‡C with 20 Wl of matrix in Tris^Ca^BSA (pH 7.4). (b) Tem-
perature: [125I](1^68) RANTES was incubated with 20 Wl of
heparin-agarose at 4‡C, 20‡C and 37‡C. (c) In£uence of pH:
3 nM [125I](1^68) RANTES were incubated with 20 Wl of hepa-
rin-agarose at pH ranging from 4 to 8.2. (d) In£uence of Ca2
concentration: 2.3 nM [125I](1^68) RANTES was incubated
with 20 Wl of heparin-agarose in Tris^BSA in the presence of
2.5, 5 or 10 mM Cl2Ca. (e) In£uence of heat-treatment of
[125I](1^68) RANTES. Results are representative as means þ
S.D. of three to four independent experiments, each performed
in duplicate.
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dency is in accordance with the occurrence of lectin^
carbohydrate interaction.
Soluble heparin signi¢cantly competed with
[125I](1^68) RANTES binding to heparin-agarose,
while chondroitin sulfate or dextran had no e¡ect,
which demonstrates the speci¢city of such interaction
(Table 4).
Soluble mannan signi¢cantly competed with
[125I](1^68) RANTES binding to mannose-divinylsul-
fone-agarose: a 18 Wg/ml concentration was required
to achieve 50% reduction of the binding; on the con-
trary, dextran had no signi¢cant e¡ect, which dem-
onstrates speci¢city (Table 4). However, sugars or
sugar derivatives such as mannose, methyl-K-man-
nose, glucose, methyl-K-glucose, galactose, methyl-
K-galactose up to 20 mM, had no e¡ect (data not
shown). Taken together, our data indicate that
RANTES speci¢cally interacts with mannan in solu-
tion and with mannose presented by an a⁄nity ma-
trix, and that these interactions strongly depend on
the carbohydrate moiety presentation.
Nevertheless, high concentrations of heparin or
chondroitin sulfate, 330 Wg/ml, also signi¢cantly
competed with [125I](1^68) RANTES binding to
mannose-divinylsulfone-agarose (Table 4), while low-
er concentrations of heparin, 40^80 Wg/ml, induced a
two-fold enhancing e¡ect on [125I](1^68) RANTES
binding to mannose-divinylsulfone-agarose (P6 0.05;
n = 3). These data demonstrate that RANTES specif-
ically interacts not only with heparin but also with
soluble chondroitin sulfate, and indicate that some
GAGs modulate RANTES binding properties to
mannose.
We next determined whether [125I](1^68) RANTES
binding to the matrices was reversed by soluble man-
nan or soluble heparin, respectively. [125I](1^68)
RANTES original preparation (9 nM) was charac-
terized as a major band by SDS-PAGE (16%) with
an apparent 8 kDa MW and as a minor one with a
16 kDa MW (Fig. 4a, lane 3); this indicates the
presence of monomers and dimers resistant to SDS
and L-mercaptoethanol treatment. In these denatur-
ing and reducing conditions, the chemokine mole-
cules eluted from heparin-agarose by soluble heparin
or from mannose-divinylsulfone-agarose by soluble
mannan, had the same migration patterns as the
original preparation (Fig. 4a, lanes 1 and 2 versus
3). These data indicate the reversibility of RANTES
Fig. 3. In£uence of physicochemical conditions on the binding
of full length (1^68) RANTES to mannose-divinylsulfone-aga-
rose. (a) RANTES concentration: [125I](1^68) RANTES was in-
cubated for 1 h at 37‡C with 20 Wl of matrix in Tris^Ca^BSA
(pH 7.4). (b) Temperature: [125I](1^68) RANTES was incubated
with 20 Wl of matrix at 4, 20 and 37‡C. (c) In£uence of pH:
3 nM [125I](1^68) RANTES were incubated with 20 Wl of man-
nose-divinylsulfone-agarose at pH ranging from 6 to 8.2. (d) In-
£uence of Ca2 concentration: [125I] RANTES was incubated
with 20 Wl of mannose-divinylsulfone-agarose in Tris^BSA in
the presence of 10 mM Cl2Ca or 10 mM EDTA. (e) In£uence
of heat-treatment of [125I](1^68) RANTES. Results are represen-
tative as means þ S.D. of three to four independent experiments,
each performed in duplicate.
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binding to the matrices by respectively heparin or
mannan.
We next further analyzed, by electrophoresis in
native conditions, the reversibility of RANTES bind-
ing to the matrices. The original [125I](1^68)
RANTES preparation (9 nM) was characterized by
PAGE (16%), as a major band of MW s 250 kDa
and as a minor di¡use one, of apparent MW between
64 and 168 kDa which indicates the presence of mul-
timers and aggregates (Fig. 4b,c, lanes 7 and 4). Sim-
ilar patterns were observed for the chemokine mole-
cules which were not bound by mannose-
divinylsulfone-agarose (Fig. 4b, lanes 1 and 2 versus
7), while the chemokine molecules bound by man-
nose-divinylsulfone-agarose and then eluted by solu-
ble mannan, were exclusively characterized as aggre-
gates of apparent MW s 250 kDa (Fig. 4b, lane 4).
No elution or slight elution from mannose-divinyl-
sulfone-agarose by bu¡er, methyl-K-mannose or dex-
tran, were observed which demonstrates that elution
by soluble mannan is speci¢c (Fig. 4b, lanes 3, 5, 6).
Moreover, the chemokine molecules bound by
heparin-agarose and eluted by soluble heparin, were
characterized in native conditions as a major band
with an apparent MW between 40 and 80 kDa and
as a minor one of apparent MW s 250 kDa (Fig. 4c,
lane 2), which indicates that these molecules are
mainly multimers, and not aggregates, as described
above for the original preparation (Fig. 4c, lane 4
versus 2). The fact that, in the same conditions, bu¡-
er supplemented or not with dextran, only eluted
from the matrix some chemokine molecules which
migrated as a minor band of apparent MW s 250
kDa, demonstrates the speci¢city of the 40^80 kDa
complex formed by RANTES with soluble heparin
(Fig. 4c, lanes 1 and 3). Furthermore, while soluble
RANTES (6 nM) preincubated for 1 h at 37‡C with
soluble mannan migrated, in native conditions, as a
major band of MW s 250 kDa, soluble RANTES
(6 nM) preincubated for 1 h at 37‡C with soluble
heparin migrated as two bands of apparent MW of
about 40 and 80 kDa (data not shown).
Taken together, these data indicate that RANTES
binding to heparin-agarose or to mannose-divinylsul-
fone-agarose is reversed in a carbohydrate-speci¢c
manner.
To further con¢rm RANTES-speci¢c interaction
with mannosylated derivatives, [125I](1^68) RANTES
was incubated in parallel with dotted mannan or
dextran. In these conditions, [125I](1^68) RANTES
interacted with dotted mannan but not with dextran
(Fig. 5, lane a, 1 versus 2). This interaction with
dotted mannan was abolished by mannan or heparin
in solution (Fig. 5, lanes b,c), as well as by RANTES
heat-denaturation (Fig. 5, lane e), but not by dextran
(Fig. 5, lane d), which demonstrates the speci¢city
Fig. 4. Reversion of [125I](1^68) RANTES binding to heparin-agarose and to mannose-divinylsulfone-agarose. (a) SDS-PAGE (16%)
of [125I](1^68) RANTES after binding to heparin-agarose, and elution by heparin (lane 1) or after binding to mannose-divinylsulfone-
agarose and elution by mannan (lane 2) or before binding to the matrices (lane 3). (b) PAGE (16%) in native conditions of [125I]-
(1^68) RANTES unbound by mannose-divinylsulfone-agarose (lanes 1 and 2) and after binding to mannose-divinylsulfone-agarose,
and elution by bu¡er (lane 3), mannan (lane 4), methyl-K-mannose (lane 5) or dextran (lane 6). [125I](1^68) RANTES before incuba-
tion with mannose-divinylsulfone-agarose (lane 7). (c) PAGE (16%) in native conditions of [125I](1^68) RANTES after binding to hep-
arin-agarose, and elution by bu¡er (lane 1), heparin (lane 2), dextran (lane 3) or before binding to heparin-agarose (lane 4). Data are
representative of two to three independent experiments.
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and involvement of RANTES three-dimensional
structure.
In order to determine whether the RANTES N-
terminus domain is involved in its GAG or man-
nose-binding properties, we have analyzed (10^68)
RANTES interactions with heparin-agarose or man-
nose-divinylsulfone-agarose. Soluble heparin or man-
nan only slightly competed with [125I] (10^68)
RANTES binding to both matrices, while chondroi-
tin sulfate or dextran had no e¡ect (Table 4).
Taken together, these data indicate speci¢c inter-
actions between full length (1^68) RANTES and
GAGs or mannose presented by mannan or an af-
¢nity matrix.
4. Discussion
Since the chemokine receptors used for entry of
HIV-1 R5 and X4 strains are respectively CCR5
and CXCR4 [1,4,5,6,8,9], we have analyzed the ef-
fects of soluble or cellular glycans or GAGs on
RANTES binding to primary CXCR4+ CCR5+
lymphocytes and macrophages as well as to
CCR53 CXCR4+ monocytic U937 cells. Neverthe-
less, it has been reported that human peripheral
blood monocytes di¡erentiated in vitro into macro-
phages and cultured in vitro for a few days express,
in addition to CCR5, other speci¢c RANTES recep-
tors such as CCR1 and CCR3 [31]. In addition, a
small proportion (about 5%) of unstimulated U937
cells responses minimally to RANTES and MIP-1K
(ligands to CCR1, CCR3, CCR4 and CCR5) where-
as no response is observed with MIP-1L, the most
speci¢c CCR5 ligand, as assessed by changes in cal-
cium £ux [31]. However, in the present study we did
not observe by cyto£uorometric analysis any labeling
of the U937 cells either by anti-CCR1 or anti-CCR3
antibodies (data not shown). These data indicate that
the CCR53 U937 cells used here do not express
RANTES receptors di¡erent from CCR5.
In the present study, we observed that (1^68)
RANTES speci¢cally bound not only to CCR5+ pri-
mary cells but also to CCR53 monocytic cells. These
binding strongly depended on the chemokine three-
dimensional structure. However, (1^68) RANTES at-
tachment to the CCR5+ cells depended as expected,
at least in part, on CCR5. In addition, we observed
that cellular GAGs, not only heparan sulfate but
also chondroitin sulfate, mediated (1^68) RANTES-
speci¢c attachment not only to the CCR53, but also
to the CCR5+ cells inasmuch as these attachments
were signi¢cantly, but partially, decreased by hepar-
itinase or chondroitinase pretreatment of the cells.
GAGs in solution, heparin or chondroitin sulfate,
also competed with (1^68) RANTES binding. How-
ever, higher concentrations of soluble GAGs were
required to achieve maximum competition of
RANTES binding to the CCR53 cells as compared
to the CCR5+ cells which indicates di¡erences in
RANTES a⁄nity for the cellular GAGs according
to their presentation by the di¡erent cells. The fact
that additivity was observed for these competitions
suggests the involvement of more than one type of
GAG in this binding. These data indicate that if the
chemokine is complexed with soluble GAGs, it will
be unable to bind cellular GAGs. They suggest that
soluble GAGs modulate RANTES binding to the
cells. Modulation of macrophage and B cell function
by GAGs has indeed been recently reported [32].
Otherwise, we observed that (1^68) RANTES
binding to the CCR53 as well as to the CCR5+ cells
was inhibited either by soluble mannan or by neur-
aminidase treatment of these cells. This suggests that
glycans, such as mannose- and sialic acid-containing
species, may be used by the chemokine at some at-
Fig. 5. Carbohydrate-speci¢c binding of [125I](1^68) RANTES
to dotted mannan. Binding of native (lane a) or heat-denatured
(lane e) [125I](1^68) RANTES to dotted mannan (1) or dextran
(2). In lanes b, c and d, RANTES was incubated with mannan,
heparin or dextran in solution.
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tachment step not only to to CCR5+ primary cells
(lymphocytes or macrophages) but also to CCR53
cell lines, in addition to cell surface GAGs.
Accordingly, we observed dose-dependent and spe-
ci¢c interactions between full length (1^68) RANTES
and either heparin- or mannose-immobilized on an
a⁄nity matrix. Heat-denaturation of the chemokine
signi¢cantly decreased its binding to both matrices,
which indicates involvement of the three-dimensional
structure.
(1^68) RANTES interaction with heparin-agarose
was pH-dependent which indicates, as expected, in-
volvement of electrostatic interactions. It was inhib-
ited by soluble heparin, but not by dextran nor by
chondroitin sulfate, which demonstrates in accor-
dance with [14], speci¢city.
(1^68) RANTES binding to mannose-divinylsul-
fone-agarose was also pH-dependent, which may be
related to an indirect e¡ect mediated by changes of
RANTES three-dimensional structure according to
pH. This binding was strongly calcium-dependent,
which is in accordance with lectin^carbohydrate in-
teractions. Indeed, it was inhibited by soluble man-
nan, with a 18 Wg/ml 50% inhibiting concentration
(C50), which is indicative of a⁄nity interactions in
the WM range. Dextran had no e¡ect, which con¢rms
speci¢city. Mannose or Me-K-Man had no e¡ect,
which indicates that RANTES interaction with gly-
cans strongly depends on their presentation. How-
ever, chondroitin sulfate also signi¢cantly inhibited
(1^68) RANTES binding to mannose-divinylsul-
fone-agarose, which strongly indicates speci¢c inter-
action between the chemokine and soluble chondroi-
tin sulfate. However, soluble heparin, depending on
its concentrations, had inhibitory or enhancing ef-
fects on (1^68) RANTES binding to mannose-di-
vinylsulfone-agarose. Taken together, these data in-
dicate that (1^68) RANTES has speci¢c binding
properties to glycans, which can be modulated by
GAGs.
The fact that mannan, heparin or chondroitin sul-
fate only slightly modify truncated (10^68) RANTES
binding to both matrices and to the CCR53 and the
CCR5+ cells strongly suggests that RANTES N-ter-
minus domain is involved in its carbohydrate binding
properties. However, the role of this domain has not
been clearly established. It has been reported that
truncation did or did not modify RANTES a⁄nity
for CCR5 [28,33]. While equivalent and/or enhanced
inhibition of SIVmac251 infection/replication in vivo
by N-terminal truncated RANTES has been reported
[34], 10-fold higher concentrations of truncated
RANTES were necessary to achieve in vitro the
same inhibitory e¡ect as full length RANTES on
HIV-1 infection of primary macrophages [28]. Never-
theless, truncated RANTES is not chemotactic [28].
The role of GAGs association in the function of
chemokines is not clearly elucidated. However, the
fact that speci¢c interactions of chemokines with
GAGs modulate receptor binding and cellular re-
sponses has been strongly suggested [14] and a spe-
ci¢c association between a chemokine, SDF-1, and
glycans such as mannan was recently suggested
[21,35]. The present study demonstrates that besides
GAGs, glycans are involved in RANTES conforma-
tion and attachment not only to CCR5+ primary
cells but also to CCR53 cells.
The physiopathological role of the glycan- and
GAG-binding properties of RANTES, which may
thus be compared to that of gp120lai and of SDF-
1, is presently under investigation. We and others
have previously reported that the suppressive e¡ect
of RANTES on HIV-1 infection by HIV R5 strains
is inhibited by enzymatic removal of GAGs from
CD4+ CCR5+ cells [15,36]. In addition, it has been
recently reported that complexes formed between
RANTES and soluble GAGs failed to induce intra-
cellular Ca2 mobilization on either glycosaminogly-
canase-treated or untreated PMBC and to stimulate
chemotaxis [36]. However, such complexes bound in
a saturable manner to glycosaminoglycanase-treated
PMBC and their binding was partially reversed by
anti-CCR5 antibody, which indicated that they rep-
resent seven-transmembrane ligands that do not ac-
tivate receptors [36]. Whether the RANTES ability to
bind to soluble or cellular glycans, described here,
also modulates cellular responses and HIV-1 infec-
tion deserves further investigation.
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